现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • Larotaxel
Larotaxel的可视化放大

Larotaxel

Larotaxel (XRP9881) 是一种紫杉烷类似物,具有抗紫杉烷抗性乳腺癌的临床前活性。Larotaxel (XRP9881) 通过促进微管蛋白装配和稳定微管发挥其细胞毒性作用,并最终通过细胞凋亡导致细胞死亡。Larotaxel (XRP9881) 具有穿越血脑屏障的能力,对 P-糖蛋白 1 的亲和力比 Docetaxel 低得多。

价格
0-1740
Larotaxel的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajce57090
  • CAS: 156294-36-9
  • 别名: XRP9881
  • 分子式: C45H53NO14
  • 分子量: 831.9
  • 纯度: >98%
  • 溶解度: DMSO: ≥ 50 mg/mL (60.10 mM)
  • 储存: Store at -20°C
  • 库存: 现货

Background

Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel[1][2][3].



[1]. Diéras V, et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol. 2008 Jul;19(7):1255-60. [2]. Morris PG, et al. Novel anti-tubulin cytotoxic agents for breast cancer. Expert Rev Anticancer Ther. 2009 Feb;9(2):175-85. [3]. Zatloukal P, et al. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J Thorac Oncol. 2008 Aug;3(8):894-901.

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服